GeoVax Labs Inc (GOVX) Actualités

GeoVax Receives Notice of Allowance For Cancer Vaccine Patent

Adds to Growing Portfolio of Intellectual Property Assets ATLANTA, Ga., Dec. 09, 2024 (GLOBE NEWSWIRE...

GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference

ATLANTA, Nov. 26, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

GeoVax Announces Positive Interim Data Review for Phase 2 Clinical Trial of COVID-19 Vaccine Booster in Patients with Chronic Lymphocytic Leukemia

GEO-CM04S1 Improved Immune Response vs mRNA Vaccine ATLANTA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- GeoVax...

GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update

Progress in GEO-CM04S1 BARDA/Project NextGen Phase 2b trial; multiple data readouts of existing COVID-19...

GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, Nov. 05, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc...

GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference

ATLANTA, Ga., Oct. 02, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

GeoVax to Participate in Upcoming Investor Conferences in September

ATLANTA, GA, Sept. 03, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market

ATLANTA, GA, Aug. 28, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage...

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Registration is Now Open for Tribe Public’s Webinar Event "Now Is Not the Time to Monkey(pox) Around" Featuring GeoVax Lab’s CEO

Company to Provide a Detailed Overview of Mpox Including Commentary on the Rapid Spread and Methods for...

GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market

ATLANTA, GA, Aug. 20, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage...

Form 4 - Statement of changes in beneficial ownership of securities